Within a multidisciplinary model of care, the treatment of HCV-infected PWID with all-oral DAA regimens is safe and highly effective. These data justify targeted efforts to enhance access to HCV treatment in this vulnerable and marginalized population.
No takes yet. Share an insight, caveat, or question.
Alimohammadi et al. (2018) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: